Navigation Links
Frost & Sullivan: Key Therapeutic Areas to Remain Strongest Drivers of CRO Revenue Growth in the United States
Date:9/21/2009

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- The economic downturn and reduction in funding for early stage projects is likely to result in a decline in growth rate across major therapeutic segments in the short-to-medium term. However, due to this lack of funding, it is unlikely that pharmaceutical and biotechnology companies will invest in in-house capabilities to conduct clinical trials. This is set to benefit contract research organizations (CROs) in obtaining continued business from this segment. Despite possible defaults on payments for projects from a few companies that could affect CROs in the short term, oncology, central nervous system, and cardiovascular are expected to remain as key therapeutic areas.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), U.S. CRO Markets - Key Therapeutic Areas, finds that the market earned revenues of over $10.91 billion in 2009 and estimates this to reach $22.87 billion in 2015. The markets covered in this research include preclinical to phase IV CRO services for pharmaceuticals and biotechnology.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Johanna Haynes at johanna.haynes@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

"The most interesting aspect of CRO market growth has been that of new sponsors - increasingly biotechnology companies and specialty pharmaceutical companies - with a demand for full services spanning the pre-clinical to the post-commercialization stage," says Frost & Sullivan Senior Industry Analyst Barath Shankar Subramanian. "This could be attributed to the limited development infrastructure with sponsors, leading to CROs being viewed as strategic partners."

Earlier, the trend in the market used to be start-up pharmaceutical and biotechnology companies out-licensing their product beyond phase I/II or getting acquired, which posed a great deal of uncertainty over the future of the project. Nowadays, companies are increasingly retaining products within their pipeline and continuing to take them closer to the market through CROs, thereby enhancing the value of the products and the company.

Despite optimistic forecasts for the market, a growing divide between patient access and studies is threatening productivity. Trials continue to become increasingly complex and global, resulting in intense competition for access to patients, new investigators, and innovative studies.

The divide between patient access and studies has been rising consistently over the past decade and could affect future studies. For studies that depend heavily on the emerging markets, this could have a negative impact on productivity by lengthening trial times. In addition, an underlying churn in existing investigators is further widening this divide.

"CROs and sponsors are looking at innovative ways to increase access to patients by partnering with patient recruitment firms," concludes Subramanian. "Service providers are also outsourcing large-scale global trials through the expanded reach of CRO partners, enabling access to an extensive patient pool."

U.S. CRO Markets - Key Therapeutic Areas is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Contract Research Organizations Markets; Global CRO Spending Trends; Global Biopharmaceutical Contract Manufacturing Market; and Strategic Analysis of Opportunities in the CRO Market - Phase 0. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. CRO Markets - Key Therapeutic Areas

N579

    Contact:

    Johanna Haynes
    Corporate Communications - North America
    P: 210.247.3870
    F: 210.348.1003
    E: johanna.haynes@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 2017 , ... On Sunday, September 24, hundreds will gather at Flo Jo ... considered the fastest woman of all time. Flo Jo passed away from complications ... the National Anthem. Mary was a contestant on the 2012 season of America’s ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... assembles Passive House buildings, and Richard Pedranti Architect (RPA), a full-service ... from the strategic partner’s Solsken Line of Model Homes . Independently, Ecocor ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is ... Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will begin ... at St. Thomas University in Miami, Florida, was selected from a pool of ...
(Date:9/22/2017)... ... ... “Cursed with a Curse: The Truth about Tithing”: a ... when breaking free from this misconception. “Cursed with a Curse: The Truth about ... Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and thought-provoking ...
(Date:9/22/2017)... ... 2017 , ... "Success Files," a short- and long-form documentary ... a disease estimated to affect the lives of more than 5 million Americans ... a leading voice in the fight for cure and research into the disease, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/9/2017)... Sept. 8, 2017 ... MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th ... offering free MRI brain scans to the public.Where:  ... parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, ...
Breaking Medicine Technology: